Previous studies showed that exenatide, used to treat type 2 diabetes, improves motor and non-motor function in Parkinson's disease (PD) patients. Now a new study has raised the prospect that exenatide might impact this debilitating disease. PD patients taking exenatide remained essentially unchanged throughout treatment and a year after the trial ended. Controls showed the expected decline in movement and cognitive ability.
Please login or register to read the rest of the article and to have access to downloads and comments.